| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2122991 | European Journal of Cancer | 2011 | 6 Pages |
Abstract
Although stopped prematurely, this randomized trial provides at first time evidence for the benefit of second-line chemotherapy as compared to BSC alone for patients with APC. OFF significantly prolonged survival time compared to BSC alone after failure of first-line therapy with gemcitabine.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Uwe Pelzer, Ingo Schwaner, Jens Stieler, Mathias Adler, Jörg Seraphin, Bernd Dörken, Hanno Riess, Helmut Oettle,